Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis

IMPORTANCE: Idelalisib is a first-in-class phosphatidylinositol 3-kinase inhibitor that received US Food and Drug Administration accelerated approval in July 2014 as a single-agent treatment for relapsed follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Serious adverse effects were repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Titas, Kim, Myung Sun, Haslam, Alyson, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028543/
https://www.ncbi.nlm.nih.gov/pubmed/36939665
http://dx.doi.org/10.1001/jamainternmed.2023.0190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028543/
https://www.ncbi.nlm.nih.gov/pubmed/36939665
http://dx.doi.org/10.1001/jamainternmed.2023.0190

Ejemplares similares